These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 34342757)

  • 1. Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes.
    Cao L; Sugumar K; Keller E; Li P; Rock L; Simpson A; Freyvogel M; Montero AJ; Shenk R; Miller ME
    Ann Surg Oncol; 2021 Oct; 28(10):5730-5741. PubMed ID: 34342757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer.
    Gwark S; Noh WC; Ahn SH; Lee ES; Jung Y; Kim LS; Han W; Nam SJ; Gong G; Kim SO; Kim HJ
    Front Oncol; 2021; 11():741120. PubMed ID: 34660302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How Effective is Neoadjuvant Endocrine Therapy (NET) in Downstaging the Axilla and Achieving Breast-Conserving Surgery?
    Montagna G; Sevilimedu V; Fornier M; Jhaveri K; Morrow M; Pilewskie ML
    Ann Surg Oncol; 2020 Nov; 27(12):4702-4710. PubMed ID: 32839900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer.
    Kim HJ; Noh WC; Lee ES; Jung YS; Kim LS; Han W; Nam SJ; Gong G-; Kim HJ; Ahn SH
    Breast Cancer Res; 2020 May; 22(1):54. PubMed ID: 32460816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer.
    Chen S; Chen CM; Yu KD; Zhou RJ; Shao ZM
    Ann Surg Oncol; 2012 Sep; 19(9):3002-11. PubMed ID: 22437200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axillary-conserving surgery is facilitated by neoadjuvant chemotherapy of breast cancer.
    Beatty JD; Precht LM; Lowe K; Atwood M
    Am J Surg; 2009 May; 197(5):637-41; discussion 641-2. PubMed ID: 19321159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of neoadjuvant versus adjuvant chemotherapy for hormone receptor-positive breast cancer: a National Cancer Database (NCDB) study.
    Zeidman M; Alberty-Oller JJ; Ru M; Pisapati KV; Moshier E; Ahn S; Mazumdar M; Port E; Schmidt H
    Breast Cancer Res Treat; 2020 Nov; 184(1):203-212. PubMed ID: 32740807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma.
    Thornton MJ; Williamson HV; Westbrook KE; Greenup RA; Plichta JK; Rosenberger LH; Gupta AM; Hyslop T; Hwang ES; Fayanju OM
    Ann Surg Oncol; 2019 Oct; 26(10):3166-3177. PubMed ID: 31342392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer.
    Cho JH; Park JM; Park HS; Park S; Kim SI; Park BW
    J Surg Oncol; 2013 Dec; 108(8):531-6. PubMed ID: 24115142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study.
    Chiba A; Hoskin TL; Heins CN; Hunt KK; Habermann EB; Boughey JC
    Ann Surg Oncol; 2017 Feb; 24(2):418-424. PubMed ID: 27663568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Age on Outcomes After Neoadjuvant Chemotherapy for Breast Cancer.
    Verdial FC; Mamtani A; Pawloski KR; Sevilimedu V; D'Alfonso TM; Zhang H; Gemignani ML; Barrio AV; Morrow M; Tadros AB
    Ann Surg Oncol; 2022 Jun; 29(6):3810-3819. PubMed ID: 35246810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns in the Use of Axillary Operations for Patients with Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A National Cancer Database (NCDB) Analysis.
    Srour MK; Tseng J; Luu M; Alban RF; Giuliano AE; Chung A
    Ann Surg Oncol; 2019 Oct; 26(10):3305-3311. PubMed ID: 31342364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database.
    LeVasseur N; Willemsma KA; Li H; Gondara L; Yip WC; Illmann C; Chia SK; Simmons C
    Clin Breast Cancer; 2019 Dec; 19(6):e683-e689. PubMed ID: 31279611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.
    Singh JC; Mamtani A; Barrio A; Morrow M; Sugarman S; Jones LW; Yu AF; Argolo D; Smyth LM; Modi S; Schweber S; Boafo C; Patil S; Norton L; Baselga J; Hudis CA; Dang C
    Oncologist; 2017 Feb; 22(2):139-143. PubMed ID: 28167568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis.
    Rusthoven CG; Rabinovitch RA; Jones BL; Koshy M; Amini A; Yeh N; Jackson MW; Fisher CM
    Ann Oncol; 2016 May; 27(5):818-27. PubMed ID: 26861597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery.
    Tadros AB; Yang WT; Krishnamurthy S; Rauch GM; Smith BD; Valero V; Black DM; Lucci A; Caudle AS; DeSnyder SM; Teshome M; Barcenas CH; Miggins M; Adrada BE; Moseley T; Hwang RF; Hunt KK; Kuerer HM
    JAMA Surg; 2017 Jul; 152(7):665-670. PubMed ID: 28423171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence and predictors of adjuvant chemotherapy use among patients treated with neoadjuvant endocrine therapy.
    Sella T; Kantor O; Weiss A; Partridge AH; Metzger O; King TA
    Breast Cancer Res Treat; 2022 Aug; 194(3):663-672. PubMed ID: 35752703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axillary Response in Patients Undergoing Neoadjuvant Endocrine Treatment for Node-Positive Breast Cancer: Systematic Literature Review and NCDB Analysis.
    Stafford A; Williams A; Edmiston K; Cocilovo C; Cohen R; Bruce S; Yoon-Flannery K; De La Cruz L
    Ann Surg Oncol; 2020 Nov; 27(12):4669-4677. PubMed ID: 32909130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy.
    Blumencranz P; Habibi M; Shivers S; Acs G; Blumencranz LE; Yoder EB; van der Baan B; Menicucci AR; Dauer P; Audeh W; Cox CE
    Ann Surg Oncol; 2023 Dec; 30(13):8353-8361. PubMed ID: 37658272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (CBCSG-036): A randomized, controlled, multicenter trial.
    Yu KD; Wu SY; Liu GY; Wu J; Di GH; Hu Z; Hou YF; Chen CM; Fan L; Tang LC; Shen ZZ; Wu KJ; Zhuang ZG; Zhang HW; Shao ZM
    Cancer; 2019 Jul; 125(13):2185-2193. PubMed ID: 30892700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.